Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
PixCell Medical
| Company | PixCell Medical |
|---|---|
| Name of analyzer | HemoScreen |
| Contact | Carmit Shpalter |
| City, State | Davie, FL |
| Phone | 754-236-9694 |
| Website | |
| Analyzer application | diagnostic use |
| Dimensions of analyzer (H × W × | 11.8 × 6.9 × 10.2 in./0.56 sq. ft. |
| Country where analyzer was | Israel/Israel |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S.* | 2018/— |
| First year analyzer sold outside | 2016/— |
| Foreign locations where company | Europe, Asia (installed in Europe, Asia) |
| Human languages (other than | — |
| Analyzer list price | — |
| • Analyzer acquisition options | purchase, reagent rental agreement |
| Training included with purchase/Total time for basic training per operator | — |
| • Follow-up training available | — |
| Parameters that analyzer tests and reports | %&# eosinophils, %&# lymphocytes, %&# monocytes, %&# neutrophils, %&# basophils, Hb, Hct, MCH, MCHC, MCV, PLT, RBC, WBC |
| Types of testing FDA cleared or approved for analyzer | blood count analysis |
| Types of body fluids FDA cleared or approved for analysis on analyzer | whole blood |
| Analytical measurement range for body fluid | — |
| Precision for body fluid | — |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | yes (5-part differential) |
| Tests available for research use only | — |
| Differential methods used | digital microscopy and computer-vision algorithms |
| Analytical measurement range: • WBC count/RBC count | WBC: 0.25–95.0 × 103/µL/RBC: 1.0–8.8 × 106/µL |
| Precision: • WBC count/RBC count | WBC: 4.0%/RBC: 1.5% |
| Accuracy: • WBC count/RBC count | — |
| Interfering substances: • WBC/RBC | no significant interference up to 50 mg/dL for bilirubin, 729 mg/dL for triglycerides/no significant interference up to 50 mg/dL for bilirubin, 729 mg/dL for triglycerides |
| • Hemoglobin/Platelets | no significant interference up to 50 mg/dL for bilirubin, 729 mg/dL for triglycerides/no significant interference up to 30 mg/dL for bilirubin, 729 mg/dL for triglycerides |
| • Hematocrit/Reticulocytes | no significant interference up to 50 mg/dL for bilirubin, 729 mg/dL for triglycerides/— |
| • Automated differential | — |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | 20/10 |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | — |
| Min. specimen volume open mode/Closed mode/Microsample capability | 40 µL/40 µL/yes |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | none/— |
| Analyzer performs delta checks | no |
| Parameters for which flags may appear | all CBC and differential parameters, pathologic flags, range flags, measurement condition flags, parameter warning, error flags |
| Analyzer recognizes and holds test results | no |
| Scattergram display uses cell-specific color | no |
| Histogram display uses color with thresholds | no |
| LIS interface formats supported | HL7 version 2, HL7 version 3, POCT-1A |
| • Middleware interface | yes (can use Radiometer Aqure, Synlab MediPOC, Siemens Healthineers POCcelerator, Telcor, Abbott RALS, RelayMed, Orchard, SCC SoftLab, others) |
| • Information transferred to LIS via middleware or LIS interface | numeric results, flagged results |
| Analyzer transmits LOINC codes for results to LIS or middleware | yes |
| Lab automation system or workcells to which analyzer has a direct interface | Abbott Diagnostics, Telcor |
| Barcode symbologies read on specimen tube | Codabar, Code 39, Code 128 |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | — (supports QR codes) |
| No. of onboard reagents required for standard specimen analysis | — |
| • Reagents ready to use/Reagent tracking method | —/barcode reader |
| Onboard diagnostics for troubleshooting | yes |
| • Manufacturer can perform diagnostics via remote access | yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/— |
| Notes | †also marketed by Thermo Fisher Scientific, Henry Schein, Medline |